SVB Wealth LLC Acquires New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SVB Wealth LLC acquired a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 60,554 shares of the biopharmaceutical company’s stock, valued at approximately $181,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ESPR. GSA Capital Partners LLP boosted its stake in Esperion Therapeutics by 159.1% during the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock valued at $1,094,000 after purchasing an additional 685,733 shares during the period. Monaco Asset Management SAM raised its holdings in shares of Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 476,477 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Esperion Therapeutics by 120.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 225,767 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Esperion Therapeutics during the third quarter valued at approximately $131,000. Finally, Jacob Asset Management of New York LLC acquired a new position in Esperion Therapeutics in the 3rd quarter valued at approximately $59,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ESPR has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Finally, Bank of America downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock opened at $2.09 on Wednesday. Esperion Therapeutics, Inc. has a twelve month low of $0.70 and a twelve month high of $3.40. The firm has a market cap of $395.85 million, a P/E ratio of -0.99 and a beta of 0.84. The firm’s 50-day simple moving average is $2.44 and its 200-day simple moving average is $1.98.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period in the prior year, the business earned ($0.76) earnings per share. On average, equities analysts forecast that Esperion Therapeutics, Inc. will post -0.68 earnings per share for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.